Takeda at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

Takeda takes part in 4 sessions at ACT 2026 in San Antonio. Its program centres on the late-stage nonclinical studies a marketing application needs, including environmental risk and worker safety assessments. It also covers responding to drug-induced liver injury during the TAK-994 clinical trials.

Organization	ACT 2026 Attendance
Takeda Tokyo, Japan
takeda.com Pharmaceutical companies Japanese global pharmaceutical company with medicines in gastroenterology, rare diseases, oncology, neuroscience and plasma-derived therapies.	Talk Mon Nov 16 2:40pm–3:15pm Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06) DILI Whodunnit: Responding to Drug Induced Liver Injury during TAK-994 Clinical Trials (S06-3) Translational safety Talk Tue Nov 17 9:00am–9:05am Part of What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09) Introduction (S09-1) Regulatory Session Tue Nov 17 9:00am–12:00pm What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09) Regulatory 9:00amIntroduction (S09-1)Takeda 9:05amImmunotoxicity Studies: Integrating Immunotoxicity Assessment into Nonclinical Safety Programs (S09-2)Charles River 9:30amEnvironmental Risk Assessment / Worker (Occupational) Safety Studies (S09-3)Takeda 9:55amAbuse Liability Assessment (S09-4)AbbVie 10:45amApplying Weight-of-Evidence and Waivers for Late-Stage Nonclinical Safety Studies (S09-5)Akkeri 11:15amStrategic Approaches for a Successful Regulatory submission (S09-6)U.S. Food and Drug Administration Talk Tue Nov 17 9:30am–9:55am Part of What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09) Environmental Risk Assessment / Worker (Occupational) Safety Studies (S09-3) Chemical risk assessment

Organization

ACT 2026 Attendance

Takeda

Tokyo, Japan

takeda.com

Pharmaceutical companies

Japanese global pharmaceutical company with medicines in gastroenterology, rare diseases, oncology, neuroscience and plasma-derived therapies.

Talk

Mon Nov 16
2:40pm–3:15pm

Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06)

DILI Whodunnit: Responding to Drug Induced Liver Injury during TAK-994 Clinical Trials (S06-3)

Translational safety

Talk

Tue Nov 17
9:00am–9:05am

Part of What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09)

Introduction (S09-1)

Regulatory

Session

Tue Nov 17
9:00am–12:00pm

What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09)

Regulatory

9:00amIntroduction (S09-1)Takeda
9:05amImmunotoxicity Studies: Integrating Immunotoxicity Assessment into Nonclinical Safety Programs (S09-2)Charles River
9:30amEnvironmental Risk Assessment / Worker (Occupational) Safety Studies (S09-3)Takeda
9:55amAbuse Liability Assessment (S09-4)AbbVie
10:45amApplying Weight-of-Evidence and Waivers for Late-Stage Nonclinical Safety Studies (S09-5)Akkeri
11:15amStrategic Approaches for a Successful Regulatory submission (S09-6)U.S. Food and Drug Administration

Talk

Tue Nov 17
9:30am–9:55am

Part of What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09)

Environmental Risk Assessment / Worker (Occupational) Safety Studies (S09-3)

Chemical risk assessment

Instantly find 20 buyers from Takeda

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction